Novo Nordisk Wins EU Nod for Monthly Hemophilia Pen as CagriSema Data Land Alongside Fresh Pipeline Deals
Published on 09/22/2026 at 03:10 | Editorial boerse-global.de
Novo Nordisk secured a European regulatory green light for a hemophilia A therapy that could reshape prophylaxis routines, even as its shares came under heavy pressure on a turbulent trading day in Copenhagen.
The Danish drugmaker's FREHEMGO (denecimig) has been cleared for treating hemophilia A, with or without inhibitors, in both adults and children. It is the first FVIIIa mimetic to offer prophylaxis on a once-monthly, once-every-two-weeks, or once-weekly schedule delivered through a prefilled disposable pen. Novo Nordisk expects to launch the product in the first European countries during the fourth quarter of 2026, with a broader EU rollout following in early 2027. A filing with the U.S. Food and Drug Administration was already submitted in September 2025.
The approval lands at a moment when the company's core obesity franchise is drawing mounting scrutiny. Shares fell 7.4% in the prior session to close at EUR 34.83, and are down 32% over a 12-month stretch. During Monday's Capital Markets Day in London, the stock slid a further 7.5% to EUR 34.79 as management laid out long-range ambitions.
Clinical Wins Meet Investor Skepticism
Those ambitions include bringing more than five blockbuster medicines to market by 2030 and generating over DKK 150 billion in additional revenue by 2035. Analysts and market participants responded coolly, according to Reuters, with attention fixed on future pricing power, potential acquisitions, and looming patent expirations for the key drug semaglutide. Future mergers and acquisitions are not factored into that revenue target.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The pipeline itself delivered encouraging results. In the REIMAGINE 5 trial, once-weekly CagriSema at a 1.0 mg/1.0 mg dose produced an estimated average weight loss of 12.4%, compared with 9.1% for patients on 5 mg of tirzepatide. The REDEFINE 9 study showed CagriSema driving a 21.0% average reduction in body weight versus just 2.0% in the placebo arm, reinforcing the clinical strength of the company's combination platform.
Sentiment had already soured before the London event. On September 11, Morgan Stanley downgraded the stock from Equal-weight to Underweight while keeping a price target of DKK 250, citing muted medium-term growth prospects and heavy reliance on semaglutide ahead of patent losses.
Deals and Cost Cuts Fill Out the Strategy
To broaden its pipeline beyond existing blockbusters, Novo Nordisk has moved quickly on several fronts. On Thursday it entered a development and licensing agreement with Orbis Medicines targeting oral cardiometabolic therapies. Orbis values the total deal at up to USD 1.4 billion, comprising upfront and milestone payments, tiered royalties, and a strategic equity stake held by Novo Nordisk. A day earlier, the company announced a collaboration with Anthropic to accelerate drug development and biological analysis through artificial intelligence.
Regulatory momentum continued on Friday, when a European Medicines Agency committee recommended approval for once-weekly Sogroya in children with persistent growth failure.
Margin Pressure Builds From Multiple Directions
The push into specialized therapeutic areas comes as the weight-loss business faces intensifying headwinds. Markus Manns, portfolio manager at Union Investment, told Reuters that the 2030 revenue target, paired with guidance for merely stable margins, is understandable but subdued given the challenges ahead. Novo Nordisk confronts biosimilar competition in Canada, Brazil, and China, plus sharper rivalry from the likes of Amgen and Pfizer starting in 2028.
Management is responding with cost reductions while expanding its oral medicine portfolio, aiming to move at least five tablet-based candidates into clinical testing before year-end. Successes such as the FREHEMGO approval underscore the need to widen the company's earnings base over the medium term to offset mounting margin pressure in obesity care.
Ad
Novo Nordisk Stock: New Analysis - 22 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
